October 2022 - Inotrem

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

October 25, 2022

Paris (France), October 25. 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the

ESICM LIVES, October 22-26, 2022, Paris (France)

October 22, 2022

Inotrem is pleased to attend the European Society of Intensive Care Medicine’s 35th Annual Congress in Paris where it will be holding a Symposium on

International Sepsis Forum/ISICIP 2022, October 13-14, 2022, Barcelona (Spain)

October 13, 2022

Inotrem welcomes you at the Symposium it will be holding during ISICIP 2022 on “Correcting Severe Immune Dysregulations in Sever Infections. The role of the

Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

October 13, 2022

Paris (France), October 13, 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first

Month: October 2022

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

ESICM LIVES, October 22-26, 2022, Paris (France)

International Sepsis Forum/ISICIP 2022, October 13-14, 2022, Barcelona (Spain)

Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

Categories

Archives